-
A review of any publication from 1960 to 2007 with the main outcome of time to fertility following oral contraceptive discontinuation was performed.
-
Arzoxifene is being developed by Eli Lilly and Co. to prevent bone loss and treat osteoporosis.
-
One of the most confusing areas in medicine, which spills over into obstetrics, is thrombophilia, and seemingly every year a new antibody affecting the clotting system emerges that causes worry. One of the worries involves a possible link with pre-eclampsia.
-
The simultaneously obtained lead II and lead V1 rhythm strip seen above was interpreted as showing atrial fibrillation with a rapid ventricular response. Do you agree?
-
The ACCORD trial has been newsworthy in the last several months primarily due to the early results of increased cardiovascular events associated with very tight glucose control.
-
Everolimus is the newest oral kinase inhibitor approved for the treatment of advanced renal cell carcinoma.
-
Almost one-fifth of Medicare patients who were discharged from a hospital were rehospitalized within 30 days, and about a third were rehospitalized within 90 days. Most of these readmissions were not planned.
-
We don't have the slightest idea whether evidence of gallbladder dyskinesia should warrant cholecystectomy or not.
-
Once-a-week rosuvastatin therapy was well tolerated in patients with a history of adverse events to one or more statins and led to significantly improved lipoprotein changes.
-
ACCORD-MIND: Memory in Diabetes; Pulmonary embolism in acute COPD exacerbations; PLCO supports USPSTF recommendations; Balloon kyphoplasty for vertebral fractures; Exercise improves QOL in CHF patients; CBT for anxiety in older adults